Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis

[1]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.

[2]  A. Ludolph,et al.  RCVS: by clinicians for clinicians—a narrative review , 2022, Journal of Neurology.

[3]  I. Ilyas,et al.  Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies , 2022, Acta Pharmacologica Sinica.

[4]  F. Arturi,et al.  Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options , 2022, Life.

[5]  Shih-Pin Chen,et al.  Pathophysiology of reversible cerebral vasoconstriction syndrome , 2022, Journal of Biomedical Science.

[6]  L. Merson,et al.  Neurological manifestations of COVID-19 in adults and children , 2022, Brain : a journal of neurology.

[7]  E. Moro,et al.  Neurologic complications of coronavirus and other respiratory viral infections , 2022, Handbook of Clinical Neurology.

[8]  Jonathan Evans,et al.  Foreign accent syndrome and other neuropsychological sequelae of a parieto-occipital lesion following COVID-19 associated posterior reversible encephalopathy syndrome , 2022, The Clinical neuropsychologist.

[9]  Sidharta Suwanto,et al.  Posterior reversible encephalopathy syndrome on COVID-19 , 2022, Radiology Case Reports.

[10]  T. Yock,et al.  Posterior reversible encephalopathy syndrome and necrotizing enterocolitis in a pediatric patient with medulloblastoma and COVID‐19 infection , 2022, Pediatric blood & cancer.

[11]  M. Mackiewicz-Milewska,et al.  A Case Report of Posterior Reversible Encephalopathy Syndrome (PRES) in a Nonsevere Case of COVID-19 , 2022, Brain sciences.

[12]  V. Lazzaro,et al.  Addressing PRES and RCVS: Two distinct entities or a spectrum of the same disease? , 2022, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[13]  Huanchun Chen,et al.  SARS-CoV-2 productively infects human brain microvascular endothelial cells , 2022, Journal of neuroinflammation.

[14]  J. Oshima,et al.  TNF‐α/IFN‐γ synergy amplifies senescence‐associated inflammation and SARS‐CoV‐2 receptor expression via hyper‐activated JAK/STAT1 , 2022, Aging cell.

[15]  D. Abdel Mohsen,et al.  AB1095 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AFTER COVID-19 VACCINATION: A CASE REPORT , 2022, Annals of the Rheumatic Diseases.

[16]  A. Mally,et al.  The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro , 2022, Archives of Toxicology.

[17]  Arvind H. Patel,et al.  The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein , 2022, bioRxiv.

[18]  A. Lund,et al.  COVID-19 Vaccination Might Induce Reversible Cerebral Vasoconstriction Syndrome Attacks: A Case Report , 2022, Vaccines.

[19]  I. Tam,et al.  Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension? , 2022, Cureus.

[20]  Dhruva Sharma,et al.  Non-hypertension-associated Posterior Reversible Encephalopathy Syndrome in COVID-19 , 2022, Indian Journal of Critical Care Medicine.

[21]  C. Kase,et al.  PRES and RCVS: Two Distinct Entities or a Spectrum of the Same Disease? , 2022, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[22]  K. Pyrshev,et al.  Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission , 2022, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[23]  A. Doria,et al.  Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection , 2022, Neurological Sciences.

[24]  F. Antochi,et al.  Posterior reversible encephalopathy syndrome – A pathology that should not be overlooked in the era of COVID-19 , 2022, The American Journal of Emergency Medicine.

[25]  Sema Aylan Gelen,et al.  Posterior reversible encephalopathy syndrome related to COVID-19 in a child. , 2022, Pediatrics international : official journal of the Japan Pediatric Society.

[26]  M. Saadatnia,et al.  Reversible Cerebral Vasoconstriction Syndrome and Multisystem Inflammatory Syndrome in Children With COVID-19 , 2022, Pediatric Neurology.

[27]  Johnson Lin,et al.  Pathogenesis of COVID‐19 described through the lens of an undersulfated and degraded epithelial and endothelial glycocalyx , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  P. Boor,et al.  Complement activation induces excessive T cell cytotoxicity in severe COVID-19 , 2021, Cell.

[29]  P. Diggikar,et al.  Hypertension Secondary to COVID-19 Leading to Posterior Reversible Encephalopathy Syndrome in a 13-year-old Male , 2022, Journal of Clinical and Diagnostic Research.

[30]  U. Demir,et al.  POSTERIOR REVERSIBL ENCEPHALOPATHY SYNDROME IN COVID 19 DISEASE: A RARE CASE , 2021, Journal of Emergency Medicine Case Reports.

[31]  E. Wan,et al.  Long-term complications of COVID-19 , 2021, American journal of physiology. Cell physiology.

[32]  J. Finsterer.  First Reported Case of Reversible Cerebral Vasoconstriction Syndrome After a SARS-CoV-2 Vaccine , 2021, Cureus.

[33]  C. Strauss,et al.  Case report of a fulminant non-aneurysmal convexity subarachnoid hemorrhage after COVID-19 , 2021, Interdisciplinary Neurosurgery.

[34]  V. Kamath,et al.  Fulminant Reversible Cerebral Vasoconstriction Syndrome in Breakthrough COVID 19 Infection , 2021, Journal of Stroke and Cerebrovascular Diseases.

[35]  Xiaobo Zhou,et al.  Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2 , 2021, Angiogenesis.

[36]  K. Karaali,et al.  A Case of COVID-19 Presenting with Posterior Reversible Encephalopathy Syndrome , 2021, Türk Nöroloji Dergisi.

[37]  A. Singhal.  Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome as Syndromes of Cerebrovascular Dysregulation , 2021, Continuum.

[38]  Hend H Alamri,et al.  Posterior Reversible Encephalopathy Syndrome: A Rare Complication in COVID-19 , 2021, Cureus.

[39]  K. Sladek,et al.  A 33-year-old in puerperium with posterior reversible encephalopathy syndrome in course of severe COVID-19. , 2021, Polish Archives of Internal Medicine.

[40]  C. Venkatasubramanian,et al.  Reversible Cerebral Vasoconstriction Syndrome in Patients with Coronavirus Disease: A Multicenter Case Series , 2021, Journal of Stroke and Cerebrovascular Diseases.

[41]  Laura Donaldson,et al.  Posterior Reversible Encephalopathy Syndrome in Acute COVID-19 Pneumonia , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[42]  A. Barilli,et al.  Endothelial Cell Activation by SARS-CoV-2 Spike S1 Protein: A Crosstalk between Endothelium and Innate Immune Cells , 2021, Biomedicines.

[43]  M. Neri,et al.  Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1β, IL-6, IL-15 and TNF-α , 2021, Forensic Science, Medicine and Pathology.

[44]  G. Romero-Sánchez,et al.  Posterior reversible encephalopathy syndrome during convalescence from COVID-19 , 2021, The International journal of neuroscience.

[45]  A. Srinivasan,et al.  Intracerebral Hemorrhage and Reversible Cerebral Vasoconstriction Syndrome in a Patient With COVID-19 , 2021, Cureus.

[46]  V. Di Lazzaro,et al.  Posterior Reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature , 2021, Journal of Neurology.

[47]  H. Yaguchi,et al.  Posterior Reversible Encephalopathy Syndrome Associated with COVID-19 in a Japanese Patient , 2021, Internal medicine.

[48]  S. Ono,et al.  Posterior Reversible Encephalopathy Syndrome: A Review of the Literature , 2021, Internal medicine.

[49]  H. Schiöth,et al.  Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms , 2021, Journal of Neuroimmunology.

[50]  A. A. A. Al haboob.  Miller Fischer and posterior reversible encephalopathy syndromes post COVID-19 infection , 2021, Neurosciences.

[51]  V. Pelak,et al.  Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID‐19: Case series and literature review , 2021, European journal of neurology.

[52]  M. Leo,et al.  SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity , 2021, Frontiers in Cardiovascular Medicine.

[53]  M. Al-Kaisy.  Posterior reversible encephalopathy syndrome due to COVID-19 , 2021, Journal of Emergency Practice and Trauma.

[54]  V. Shankar,et al.  Eclampsia and posterior reversible encephalopathy syndrome in a parturient complicated by SARS COVID-19 pneumonia , 2021, Brazilian Journal of Anesthesiology (English Edition).

[55]  P. Muntendam,et al.  Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein , 2021, Biomedicines.

[56]  A. Koyanagi,et al.  Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. , 2021, European review for medical and pharmacological sciences.

[57]  I. Karakis,et al.  Posterior Reversible Leukoencephalopathy Syndrome in a Patient after Acute COVID-19 Infection , 2021, Case reports in neurological medicine.

[58]  O. Hussein,et al.  COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin , 2021, Journal of Stroke and Cerebrovascular Diseases.

[59]  A. Abdulsalam,et al.  Posterior reversible encephalopathy syndrome overshadowing COVID-19: An Abstruse scenario or a conspicuous association? , 2021, Neurosciences.

[60]  A. Malhotra,et al.  SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2 , 2021, Circulation research.

[61]  J. Siegler,et al.  Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19 , 2021, Journal of Clinical Neuroscience.

[62]  N. Kocer,et al.  Posterior Reversible Encephalopathy Syndrome in a Pediatric COVID-19 Patient. , 2021, The Pediatric infectious disease journal.

[63]  N. Issa,et al.  Rapid development of seizures and PRES in a COVID-19 patient , 2021, Epilepsy & Behavior Reports.

[64]  A. Rajakumar,et al.  Acute hemorrhagic leukoencephalitis in a COVID-19 patient—a case report with literature review , 2021, Neuroradiology.

[65]  L. Nichols,et al.  Posterior Reversible Encephalopathy Syndrome in a Patient With SARS-CoV-2 Infection Treated With Tocilizumab , 2021, Cureus.

[66]  A. Kerro.  Encephalopathy with progression to posterior reversible encephalopathy pattern in a patient with COVID-19: clinical, imaging findings and follow-up , 2021, BMJ Case Reports.

[67]  N. Jha,et al.  Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations , 2021, Journal of Molecular Neuroscience.

[68]  K. Schroder,et al.  Endothelial cells are not productively infected by SARS‐CoV‐2 , 2021, Clinical & translational immunology.

[69]  T. Hassan,et al.  COVID-19-related Posterior Reversible Encephalopathy Syndrome in an Adult ICU Patient in Ireland. , 2021, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[70]  N. Archibald,et al.  Persistent Cortical Blindness Following Posterior Reversible Encephalopathy Syndrome (PRES) as a Complication of COVID-19 Pneumonia , 2021, Cureus.

[71]  M. Bhowmick,et al.  Guillain-barre syndrome and posterior reversible encephalopathy syndrome associated with COVID-19: Expanding horizon of the novel disease , 2021 .

[72]  N. Bresolin,et al.  Posterior reversible encephalopathy syndrome and COVID-19: A series of 6 cases from Lombardy, Italy , 2020, eNeurologicalSci.

[73]  E. Marchiori,et al.  COVID-19 and Posterior Reversible Encephalopathy Syndrome. , 2020, Neurology. Clinical practice.

[74]  L. Cruz,et al.  Posterior reversible encephalopathy syndrome in a patient submitted to extracorporeal membrane oxygenation for COVID-19. , 2021, Revista Brasileira de terapia intensiva.

[75]  T. Wijeratne,et al.  Case Report: Posterior Reversible Leukoencephalopathy Syndrome (PRES) as a Biologically Predictable Neurological Association in Severe COVID-19. First Reported Case From Australia and Review of Internationally Published Cases , 2021, Frontiers in Neurology.

[76]  N. Le,et al.  SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress , 2020, Frontiers in Physiology.

[77]  D. Dias,et al.  Hemorrhagic PRES: an unusual neurologic manifestation in two COVID-19 patients. , 2020, Arquivos de Neuro-Psiquiatria.

[78]  E. J. Belin de Chantemèle,et al.  HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation , 2020, Journal of the American Heart Association.

[79]  A. Rai,et al.  Postpartum Atypical Posterior Reversible Encephalopathy Syndrome in a COVID-19 Patient – An Obstetric Emergency , 2020, Journal of Stroke and Cerebrovascular Diseases.

[80]  J. Benito-León,et al.  Hallucinatory palinopsia in COVID-19 induced posterior reversible encephalopathy syndrome. , 2020, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[81]  D. Dutta,et al.  Initial testing of an electronic application of the simplified modified Rankin Scale questionnaire (e-smRSq). , 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[82]  Laura Llansó,et al.  Posterior Reversible Encephalopathy Syndrome in COVID-19 Disease: a Case-Report , 2020, SN Comprehensive Clinical Medicine.

[83]  S. Avignone,et al.  COVID-19–Associated PRES–like Encephalopathy with Perivascular Gadolinium Enhancement , 2020, American Journal of Neuroradiology.

[84]  L. Ordóñez-Boschetti,et al.  Associated posterior reversible encephalopathy syndrome (PRES) to SARS-CoV-2. Case report , 2020, Neurología (English Edition).

[85]  M. Mauri,et al.  Pressing Issues in COVID-19: Probable Cause to Seize SARS-CoV-2 for Its Preferential Involvement of Posterior Circulation Manifesting as Severe Posterior Reversible Encephalopathy Syndrome and Posterior Strokes , 2020, American Journal of Neuroradiology.

[86]  D. Chung,et al.  Posterior Reversible Encephalopathy Syndrome in Patients with Coronavirus Disease 2019: Two Cases and A Review of The Literature , 2020, Journal of Stroke and Cerebrovascular Diseases.

[87]  H. Hosseini,et al.  Posterior reversible encephalopathy syndrome associated with SARS-CoV-2 infection , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[88]  P. Belani,et al.  Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis , 2020, Clinical Imaging.

[89]  V. López Pérez,et al.  Postpartum consciousness disturbance: can covid-19 cause posterior reversible encephalopathy syndrome? , 2020, Revista Española de Anestesiología y Reanimación.

[90]  V. López Pérez,et al.  Alteración del nivel de conciencia puerperal: ¿puede el COVID-19 ser causa de síndrome de encefalopatía posterior reversible? , 2020, Revista Española de Anestesiología y Reanimación.

[91]  M. Zheng,et al.  Extrapulmonary complications of COVID‐19: A multisystem disease? , 2020, Journal of medical virology.

[92]  D. Leifer,et al.  Posterior reversible encephalopathy syndrome in patients with COVID-19 , 2020, Journal of the Neurological Sciences.

[93]  L. Zou,et al.  Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients , 2020, The Journal of infectious diseases.

[94]  G. Tung,et al.  Posterior Reversible Encephalopathy Syndrome: A Manifestation of COVID-19 Cytokine Storm , 2020, Interdisciplinary Neurosurgery.

[95]  V. Hernando-Requejo,et al.  Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient , 2020, Seizure.

[96]  S. Mayer,et al.  Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection , 2020, Journal of Stroke and Cerebrovascular Diseases.

[97]  Anant M. Shenoy,et al.  Posterior reversible encephalopathy syndrome in severe SARS-COV-2 infection , 2020, Journal of the Neurological Sciences.

[98]  M. Castillo,et al.  Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection , 2020, American Journal of Neuroradiology.

[99]  A. Kocaman,et al.  Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report , 2020, Journal of the Neurological Sciences.

[100]  C. Chung,et al.  Temporal Profile of Blood-Brain Barrier Breakdown in Reversible Cerebral Vasoconstriction Syndrome , 2020, Stroke.

[101]  A. Cyr,et al.  Nitric Oxide and Endothelial Dysfunction. , 2020, Critical care clinics.

[102]  F. Pilato,et al.  Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Considerations , 2020, Frontiers in Neurology.

[103]  G. Marca,et al.  Reversible Cerebral Vasoconstriction Syndrome: A Severe Neurological Complication in Postpartum Period , 2020, Neurology India.

[104]  M. Tanios,et al.  245: Posterior Reversible Encephalopathy Syndrome as a Late Sequela of COVID-19 , 2020 .

[105]  G. Della Marca,et al.  Acute radiological pattern and outcome in posterior reversible encephalopathy syndrome patients , 2019, Clinical Neurology and Neurosurgery.

[106]  S. Tetsuka,et al.  Posterior reversible encephalopathy syndrome: A review with emphasis on neuroimaging characteristics , 2019, Journal of the Neurological Sciences.

[107]  M. Murad,et al.  Methodological quality and synthesis of case series and case reports , 2018, BMJ Evidence-Based Medicine.

[108]  C. Hirzel,et al.  Posterior reversible encephalopathy syndrome in an HIV-infected patient on antiretroviral treatment: what is the risk factor? , 2018, BMJ Case Reports.

[109]  A. McKinney,et al.  Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years? , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[110]  A. Singhal,et al.  Coexisting vascular lesions in reversible cerebral vasoconstriction syndrome , 2017, Cephalalgia : an international journal of headache.

[111]  M. Endres,et al.  Factors associated with fatal outcome in posterior reversible encephalopathy syndrome: a retrospective analysis of the Berlin PRES study , 2017, Journal of Neurology.

[112]  E. Schmutzhard,et al.  Posterior reversible encephalopathy syndrome , 2017, Journal of Neurology.

[113]  S. Fowler,et al.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature , 2016, The neurologist.

[114]  A. Singhal,et al.  Long-term outcomes after reversible cerebral vasoconstriction syndrome , 2016, Cephalalgia : an international journal of headache.

[115]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[116]  Derek M. Sorensen.  Reversible Cerebral Vasoconstriction Syndrome. , 2016, JAMA neurology.

[117]  H. Chabriat,et al.  Reversible cerebral vasoconstriction syndrome in the context of recent cerebral venous thrombosis: Report of a case , 2016, Cephalalgia : an international journal of headache.

[118]  N. Skeik,et al.  Postpartum reversible cerebral vasoconstriction syndrome: Review and analysis of the current data , 2015, Vascular medicine.

[119]  Yen-Feng Wang,et al.  Oxidative stress and increased formation of vasoconstricting F2-isoprostanes in patients with reversible cerebral vasoconstriction syndrome. , 2013, Free radical biology & medicine.

[120]  J. Mandrekar,et al.  Blood pressure fluctuations in posterior reversible encephalopathy syndrome. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[121]  Marie-GermaineBousser,et al.  Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome , 2010 .

[122]  D. Kallmes,et al.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. , 2010, Mayo Clinic proceedings.

[123]  H. Leung,et al.  Reversible Cerebral Vasoconstriction Syndrome with Posterior Leucoencephalopathy after Oral Contraceptive Pills , 2010, Cephalalgia : an international journal of headache.

[124]  Aseem Sharma,et al.  Imaging pattern of intracranial hemorrhage in the setting of posterior reversible encephalopathy syndrome , 2010, Neuroradiology.

[125]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[126]  W. Bartynski.  Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema , 2008, American Journal of Neuroradiology.

[127]  D. Dormont,et al.  Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature , 2008, Lupus.

[128]  R. Ho,et al.  Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. , 2007, Rheumatology.

[129]  F. Fadel,et al.  Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[130]  R. Porcher,et al.  The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. , 2007, Brain : a journal of neurology.

[131]  A. Rabinstein,et al.  Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[132]  C. Bodkin,et al.  SIROLIMUS-INDUCED POSTERIOR REVERSIBLE ENCEPHALOPATHY , 2007, Neurology.

[133]  M. Levine,et al.  Dural Puncture Headache, Postpartum Angiopathy, Pre-Eclampsia and Cortical Vein Thrombosis After an Uncomplicated Pregnancy , 2007, Cephalalgia : an international journal of headache.

[134]  P. Bergethon,et al.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. , 2006, Archives of neurology.

[135]  M. Gladwin,et al.  Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects. , 2006, The Journal of infectious diseases.

[136]  Heidi M Crane,et al.  Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy , 2006, AIDS.

[137]  C. Ozcan,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[138]  A. Singhal,et al.  Postpartum angiopathy and other cerebral vasoconstriction syndromes , 2005, Neurocritical care.

[139]  A. Lumsden,et al.  HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. , 2004, Cardiovascular research.

[140]  J. Hawley,et al.  Thrombotic thrombocytopenic purpura-induced posterior leukoencephalopathy in a patient without significant renal or hypertensive complications. , 2004, Journal of postgraduate medicine.

[141]  A. Lumsden,et al.  HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[142]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[143]  J. Port,et al.  Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[144]  G. Sobue,et al.  Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. , 1998, AJNR. American journal of neuroradiology.

[145]  E. Arnoldus,et al.  A reversible posterior leukoencephalopathy syndrome. , 1996, The New England journal of medicine.

[146]  P. Barnes,et al.  Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. , 1995, AJR. American journal of roentgenology.

[147]  P. Purdy,et al.  Postpartum Cerebral Angiopathy: Is There a Role for Sympathomimetic Drugs? , 1993, Stroke.

[148]  L. Caplan,et al.  Basilar artery narrowing and hyperparathyroidism: illustrative case. , 1986, Stroke.